Anti-CD47 Antibody, clone 2E14 ZooMAb^® Rabbit Monoclonal

ZooMAb^® antibodies represent an entirely new generation of recombinant monoclonal antibodies. Each ZooMAb^® antibody is manufactured using our proprietary recombinant expression system, purified to homogeneity, and precisely dispensed to produce robust and highly reproducible lot-to-lot consistency. Only top-performing clones are released for use by researchers. Each antibody is validated for high specificity and affinity across multiple applications, including its most commonly used application. ZooMAb^® antibodies are reliably available and ready to ship when you need them.

Leukocyte surface antigen CD47 (UniProt: Q08722; also known as Antigenic surface determinant protein OA3, Integrin-associated protein (IAP), Protein MER6) is encoded by the CD47 (also known as MER6) gene (Gene ID: 961) in human. CD47 is a transmembrane glycoprotein belonging to the immunoglobulin superfamily. It consists of an extracellular immunoglobulin variable (IgV) domain, five hydrophobic transmembrane domains, and a short intracellular C-terminal domain. CD47 is ubiquitously expressed across various tissues and plays a critical role in cellular processes such as adhesion, migration, proliferation, apoptosis, and immune regulation. It functions as a don′t eat me signal by binding to signal regulatory protein alpha (SIRP ) on macrophages, thereby inhibiting phagocytosis of host cells. This interaction is central to its involvement in tumor immune evasion, making CD47 a prominent target in cancer immunotherapy. CD47 interacts with multiple binding partners, including thrombospondin-1 (TSP-1) and integrins such as vβ3, 2β1, and 5β1, regulating cellular adhesion and response to extracellular matrix proteins. Its signaling pathways include calcium homeostasis, cyclic nucleotide signaling, nitric oxide production, and angiogenesis, linking CD47 to vascular development and inflammation. Overexpression of CD47 has been observed in various malignancies, including colorectal cancer, leukemia, and glioblastoma, where it correlates with enhanced tumor progression and immune cell infiltration. CD47 expression has also been implicated in the activation of oncogenic pathways, such as the mitogen-activated protein kinase (MAPK), phosphoinositide 3-kinase (PI3K), and transforming growth factor-beta (TGF-β) pathways, further contributing to tumor growth and immune suppression. Beyond cancer, CD47 plays a role in non-neoplastic diseases, including autoimmune disorders and cardiovascular diseases, where its modulation impacts inflammatory and apoptotic pathways. This ZooMAb^® recombinant monoclonal antibody, generated by our proprietary technology, offers significantly enhanced specificity, affinity, reproducibility, and stability over conventional monoclonals.

We are committed to bringing you greener alternative products, which adhere to one or more of the 12 Principles of Green Chemistry. This antibody is preservative-free, produced without the harm or sacrifice of animals and exceptionally stable to allow for ambient shipping and storage if needed, and thus aligns with "Waste Prevention", "Designing Safer Chemicals" and "Design for Energy Efficiency". Click here for more information.

KLH-conjugated linear peptide corresponding to 15 amino acids from the N-terminal half of human CD47.

Quality Control Testing
Evaluated by Western Blotting in U-251 MG cell lysate.

Western Blotting Analysis: A 1:1,000 dilution of this antibody detected CD47 in U-251 MG cell lysate.

Tested Applications
Western Blotting Analysis: A 1:1,000 dilution from a representative lot detected CD47 in human spleen tissue lysate.
Affinity Binding Assay: A representative lot of this antibody bound with CD47 peptide with at least one hundred thousand-fold (100,000X) higher affinity than with non-specific control peptide.

Flow Cytometry Analysis: 1 µg from a representative lot detected CD47 in one million human peripheral blood mononuclear cells (PBMC).

Immunocytochemistry Analysis: A 1:100 Dilution from a representative lot detected CD47 in MCF7 cells.

Note: Actual optimal working dilutions must be determined by end user as specimens and experimental conditions may vary with the end user.

Clone 2E14 is a ZooMAb^® rabbit recombinant monoclonal antibody that detects CD47. It targets an epitope within 15 amino acids from the N-terminal half.

Purified recombinant rabbit monoclonal antibody IgG, lyophilized in PBS with 5% Trehalose, normal appearance a coarse or translucent resin. The PBS/trehalose components in the ZooMAb formulation can have the appearance of a semi-solid (bead like gel) after lyophilization. This is a normal phenomenon. Please follow the recommended reconstitution procedure in the data sheet to dissolve the semi-solid, bead-like, gel-appearing material. The resulting antibody solution is completely stable and functional as proven by full functional testing. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 µL.

300 µg/mL after reconstitution at 25 µL per vial. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.

Recommend storage of lyophilized product at 2-8°C; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 µL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8°C, or -20°C for long term storage. Avoid repeated freeze-thaws.

ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.